Ideaya Biosciences Inc (NASDAQ:IDYA) — Market Cap & Net Worth
Market Cap & Net Worth: Ideaya Biosciences Inc (IDYA)
Ideaya Biosciences Inc (NASDAQ:IDYA) has a market capitalization of $2.47 Billion ($2.47 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5405 globally and #1789 in its home market, demonstrating a -2.01% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ideaya Biosciences Inc's stock price $35.50 by its total outstanding shares 87860920 (87.86 Million). See Ideaya Biosciences Inc capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Ideaya Biosciences Inc Market Cap History: 2019 to 2026
Ideaya Biosciences Inc's market capitalization history from 2019 to 2026. Data shows growth from $658.96 Million to $3.12 Billion (17.41% CAGR).
Index Memberships
Ideaya Biosciences Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.10% | #138 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.01% | #615 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.14% | #88 of 263 |
Weight: Ideaya Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ideaya Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ideaya Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.89x
Ideaya Biosciences Inc's market cap is 13.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.23 Billion | $19.54 Million | -$32.27 Million | 62.96x | N/A |
| 2021 | $2.08 Billion | $27.94 Million | -$47.53 Million | 74.34x | N/A |
| 2022 | $1.60 Billion | $50.93 Million | -$54.81 Million | 31.35x | N/A |
| 2023 | $3.13 Billion | $23.39 Million | -$112.96 Million | 133.68x | N/A |
| 2024 | $2.26 Billion | $7.00 Million | -$274.48 Million | 322.58x | N/A |
| 2025 | $3.04 Billion | $218.71 Million | -$113.70 Million | 13.89x | N/A |
Competitor Companies of IDYA by Market Capitalization
Companies near Ideaya Biosciences Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Ideaya Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Ideaya Biosciences Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Ideaya Biosciences Inc's market cap moved from $658.96 Million to $ 3.12 Billion, with a yearly change of 17.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.12 Billion | +2.69% |
| 2025 | $3.04 Billion | +34.51% |
| 2024 | $2.26 Billion | -27.77% |
| 2023 | $3.13 Billion | +95.82% |
| 2022 | $1.60 Billion | -23.14% |
| 2021 | $2.08 Billion | +68.86% |
| 2020 | $1.23 Billion | +86.67% |
| 2019 | $658.96 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Ideaya Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.47 Billion USD |
| MoneyControl | $2.47 Billion USD |
| MarketWatch | $2.47 Billion USD |
| marketcap.company | $2.47 Billion USD |
| Reuters | $2.47 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and … Read more